ILD IS A COMMON, EARLY, AND POTENTIALLY FATAL MANIFESTATION OF SSc1-3

SSc-ILD
THREE DISTINCT AND INTERCONNECTED PATHWAYS DRIVE THE PROGRESSION OF PULMONARY FIBROSIS IN SSc-ILD4
Diagram Disease
Diagram Disease
FIBROTIC DAMAGE OCCURS EARLY3
Diagram SSc Diagram SSc

Adapted from Jaeger VK et al. PLoS One. 2016;11(10):1-15.

Pulmonary involvement was evident in the majority of patients 1 year after the onset of Raynaud’s phenomenon3
Diagram Classification
THE RISK OF DEVELOPING ILD IS HIGH1
Diagram SSc Diagram SSc
SSc‑ILD IS THE LEADING CAUSE OF SSc‑RELATED DEATHS2
Diagram SSc 2 Diagram SSc
Vigilant monitoring of patients with SSc is necessary to identify ILD early5
Diagram Classification
arrow
arrow

dcSSc, diffuse cutaneous systemic sclerosis; DLco, diffusing capacity for carbon monoxide; FVC, forced vital capacity; ILD, interstitial lung disease; lcSSc, limited cutaneous systemic sclerosis; SSc, systemic sclerosis.

References: 1. Walker UA et al. Ann Rheum Dis. 2007;66(6):754-763. 2. Tyndall AJ et al. Ann Rheum Dis. 2010; 69(10):1809-1815. 3. Jaeger VK et al. PLoS One. 2016;11(10):1-15. 4. Bagnato G et al. Eur Respir Rev. 2015;24(135):102-114. 5. Silver KC. Rheum Dis Clin North Am. 2015;41(3):439-457.